New Pharmacotherapeutic Posssibilities in Contemporary Dentistry
Authors:
R. Slezák; Z. Janovská; I. Lindrová; V. Radochová
Authors place of work:
Stomatologická klinika LF UK a FN, Hradec Králové
Published in the journal:
Česká stomatologie / Praktické zubní lékařství, ročník 115, 2015, 3, s. 27-33
Category:
Review Article
Věnováno doc. MUDr. J. Bittnerovi, CSc., k významnému životnímu jubileu.
Summary
Background:
Both new active substances and medical devices are used in dentistry. Especially some diseases of the mucous membrane of the mouth, lip vermillion, salivary glands, and bone of jaws are the major focus on drug development. An acyclic nucleoside antiviral analogue Zovirax Duo containing aciclovir and cortisol is the cream peparation for topical treatment of labial herpes with additional antiinflammatory effect. Filmogel® URGO Afty gel was designed for topical therapy of recurrent aphthous ulcers. Emofix gel was designed for local therapy of mucosal bleeding of various origin. Betaine, xylitol and olive oil containing products (Xerostom) have been declared for both substitutional and stimulating therapy of hyposialia of various origin. There are initial reports about the use of bone anabolic drug teriparatide, recombinant agent used for the therapy of severe skeletal defects in osteoporosis, in dental surgery. Biologic agents belimumab, abatacept, and epratuzumab are clinically tested in active forms of primary Sjőgren´s syndrome. Live atenuated vaccine targeted against varicella-zoster virus in older individuals serves in the prophylaxis of the herpes zoster.
Conclusion:
Potential benefit of the above mentioned substances and devices might be seen in dental medicine disciplines.
Keywords:
aciclovir – cortisol – labial herpes – herpes simplex virus – varicella-zoster virus – herpes zoster – recurrent aphthous ulcers – gingivectomy – periodontology – hyposialia – xerostomia – Sjőgren´s syndrome – substitution – stimulation – teriparatide – osteonecrosis – jaw bone – biologic therapy – belimumab – abatacept – epratuzumab – clinical study – active substance – medical device – local therapy – systemic therapy
Zdroje
1. Bashutski, J. D., Eber, R. M., Kinney, J. S., Benavides, E., Maitra, S., Braun, T. M., Giannobile, W. V., McCauley, L. K.: Teriparatide and osseous regeneration in the oral cavity. N. Engl. J. Med., roč. 363, 2010, č. 25, s. 2396–2405.
2. DGM Italia. http://www.dmgit.com
3. Evans, T. G., Bernstein, D. I, Raborn, G. W., Harmenberg, J., Kowalski, J., Spruance, S. L.: Double-blind, randomized, placebo-controlled study of topical 5% aciclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis. Antimicrob. Agents Chemother., roč. 46, 2002, č. 6, s. 1870–1874.
4. Hull, C. M., Brunton, S.: The role of topical 5% acyclovir and 1% hydrocortisone cream (Xerese™) in the treatment of recurrent herpes simplex labialis. Postgrad. Med., roč. 122, 2010, č. 5, s. 1–6.
5. Kost, R. G., Straus, S. E.: Postherpetic neuralgia–pathogenesis, treatment, and prevention. N. Engl. J. Med., roč. 335, 1996, č. 1, s. 32–42.
6. Levin, M. J., Smith, J. G., Kaufhold, R. M., Barber, D., Hayward, A. R., Chan, C. Y., et al.: Decline in varicella-zoster virus (VZV) – specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J. Infect. Dis., roč. 188, 2003, č. 9, s. 1336–1344.
7. Mariette, X., Seror, R., Quartuccio, L., Baron, G., Salvin, S., Fabris, M., Desmoulins, F., Nocturne, G., Ravaud, P., De Vita, S.: Efficacy and safety of belimumab in primary Sjögren‘s syndrome: results of the BELISS open-label phase II study. Ann. Rheum. Dis., roč. 74, 2015, č. 3, s. 526–531.
8. Meijer, J. M., Pijpe, J., Bootsma, H., Vissink, A., Kallenberg, C. G. M.: The future of biologic agents in the treatment of Sjögren‘s syndrome. Clin. Rev. Allergy Immunol., roč. 32, 2007, č. 3, s. 292–297.
9. Meiners, P. M., Vissink, A., Kroese, F. G., Spijkervet, F. K., Smitt-Kamminga, N. S., Abdulahad, W. H., Bulthuis-Kuiper, J., Brouwer, E., Arends, S., Bootsma, H.: Abatacept treatment reduces disease activity in early primary Sjögren‘s syndrome (open-label proof of concept ASAP study). Ann. Rheum. Dis., roč. 73, 2014, č. 7: s. 1393–1396.
10. Miller, C. S.: Teriparatide‘s potential role in jaw bone related diseases. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., roč. 112, 2011, č. 6, s. 703–705.
11. Narongroeknawin, P., Danila, M. I., Humphreys, L. G., Jr., Barasch, A., Curtis, J. R.: Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. Spec. Care Dent., roč. 30, 2010, č. 2, s. 77–82.
12. Ohbayashi, Y., Miyake, M., Sawai, F., Minami, Y., Iwasaki, A., Matsui, Y.: Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw. Oral Surg. Oral Med. Oral Pathol. Oral Radiol., roč. 115, 2013, č. 4, s. 31–37.
13. Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., et al.: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med., roč. 352, 2005, č. 22, s. 2271–2284.
14. Oxman, M. N., Levin, M. J. Shingles Prevention Study Group.: Vaccination against herpes zoster and postherpetic neuralgia. J. Infect. Dis., roč. 197, 2008, Suppl. 2, s. S228–S236.
15. Rosa, J.: Teriparatid. Remedia, roč. 18, 2008, č. 5, s. 338–344.
16. Ship, J. A., McCutcheon, J. A., Spivakovsky, S., Kerr, A. R.: Safety and effectiveness of topical dry mouth products containing olive oil, betaine, and xylitol in reducing xerostomia for polypharmacy-induced dry mouth. J. Oral. Rehab., roč. 34, 2007, č. 10, s. 724–732.
17. Slezák, R., Berglová, I., Krejsek, J.: Xerostomie, hyposialie, sicca syndrom–kvantitativní poruchy salivace. Vnitř. Lék., roč. 57, 2011, č. 4, s. 339–346.
18. Slezák, R., Lindrová, I., Buchta, V., Paulusová, V., Šustová, Z., Kopecký, O., Ryšková, L.: Přehled novějších možností ve farmakoterapii nemocí ústní sliznice, slinných žláz a parodontu. Čes. Stomat., roč. 113, 2013, č. 3, s. 64–73.
19. Slezák, R., Ryšková, L., Paulusová, V., Šustová, Z., Berglová, I., Buchta, V.: Nové možnosti ve farmakoterapii chorob parodontu a ústní sliznice. Čes. Stomat., roč. 112, 2012, č. 2, s. 15–22.
20. Slezák, R., Šustová, Z., Nováková, V.: Pokroky ve farmakoterapii chorob ústní sliznice. Čes. Stomat., roč. 109, 2009, č. 1, s. 7–14.
21. Steinfeld, S. D., Tant, L., Burmeister, G. R., Teoh, N. K. W., Wegener, W. A., Goldenberg, D. M., Pradier, O.: Epratuzumab (humanized anti-CD22 antibody) in primary Sjogren‘s syndrome: An open-label Phase I/II study. Arthritis Res. Therap., roč. 8, 2006, č. 4, s. R129. doi:10.1186/ar2018.
22. Subramanian, G., Cohen, H. V., Quek, S. Y.: A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide‘s potential role in its resolution. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., roč. 112, 2011, č. 6, s. 744–753.
25. URGO. http://www. filmogel.com
26. Weller, T. H.: Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus. N. Engl. J. Med., roč. 335, 1983, č. 23, s. 1434–1440.
Štítky
Maxillofacial surgery Orthodontics Dental medicineČlánok vyšiel v časopise
Czech Dental Journal
2015 Číslo 3
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Najčítanejšie v tomto čísle
- Impacted Canines
-
Dental Caries Prevention Strategies, Application of Evidence-Based Medicine
Part II. Current Treatment, Preventive and Prophylactic Technologies. Fluorides. - New Pharmacotherapeutic Posssibilities in Contemporary Dentistry
- The Incidence of Agenesis of Third Molars in Students of Dentistry at Palacký University in Olomouc